i want to
live librarian help
Tissue engineering holds incredible potential for repairing birth defects, allowing a child’s own cells to be used to “grow” new tissue or organs for repair.
Nationwide Children’s Tissue Engineering Program leaders, Christopher Breuer, MD, and Toshiharu Shinoka, MD, PhD, were the first in the world to tissue engineer blood vessels and implant them in human infants for repair of congenital heart defects. Now, Nationwide Children’s is home to the first FDA-approved U.S. human trial to investigate the safety and effectiveness of using tissue engineering to repair congenital heart defects.
This program has the potential to drastically minimize complications that arise from the current need to use synthetic materials in surgery, including lack of growth capacity, blood clotting, increased risk of infection and poor durability.
Third International Symposium on Vascular Tissue Engineering
The Third International Symposium on Vascular Tissue Engineering (ISVTE) that will be held on June 5-6, in Columbus, Ohio, at Nationwide Children’s Hospital. The meeting will bring together biologists, engineers as well as clinicians that are active in the field of vascular tissue engineering.